Centre of Regulatory Excellence

The Centre of Regulatory Excellence (CoRE) is the first dedicated Asian Centre targeted at the needs of the national health regulators, the biomedical industry and pharmaceutical and medical device companies.  Formally inaugurated in November 2014, CoRE offers itself as a neutral platform in the academic setting of Duke-NUS Medical School.  

The Centre’s mission is to help establish regional platforms and networks to build competencies, enhance collaboration and promote thought leadership in innovative regulatory science and policy within national regulatory agencies, industry and academia. Since its inception, CoRE has organised and hosted key events advancing regulatory excellence and promoting regulatory innovation in ASEAN and Asia-Pacific.

Aligned with the succinct vision of Duke-NUS’ “Transforming Medicine, Saving lives”, CoRE focuses on being a neutral scientific regulatory entity, “Enabling regulatory excellence, Improving lives”. Ultimately, CoRE aims to create an environment in which new healthcare products can be developed, commercialised and delivered to populations across Asia with greater efficacy and safety.

For the latest happenings at CoRE, be sure to follow our Facebook page & LinkedIN or log onto our website through the underlying link.

 


 

The CoRE team lead by Associate Professor John Lim, and Associate Professor Silke Vogel, complement each other’s experience to successfully guide the Centre. Associate Professor John Lim, Executive Director of CoRE holds the concurrent appointment of Deputy Director of Medical Services (Industry & Research Matters) in the Singapore Ministry of Health. He brings significant experience from his previous role as Chief Executive Officer of Singapore’s Health Sciences Authority, which he led for eight years during a period of major development and growth. With the establishment of CoRE, Associate Professor Silke Vogel was appointed Deputy Director for the Centre, in addition to her existing role as Associate Dean of the Office of Graduate Studies at Duke-NUS. Her previous experiences included research and administration at the Department of Medicine at Columbia University, USA. 

Guided by its mission, CoRE envisions to create a conducive platform to meet the needs of its stakeholders, especially senior regulatory professionals in the industry and national regulatory authorities. This necessitated the formation and engagement of an Advisory Board to provide CoRE with long term strategic guidance to enhance regulatory leadership capabilities, provide a neutral platform for sharing of innovation, best practices and promote regulatory excellence in Asia. 

The Advisory Board, set up in November 2014 and chaired by Professor Sir Alasdair Breckenridge, former Chairman of the UK Medicines and Health Products Regulatory Agency, comprises of key leaders with experience in regulatory agencies, industry and academia. Recently appointed to this Board are Dr. Margaret Hamburg, Foreign Secretary, National Academy of Medicine & Immediate Past Commissioner US FDA and Mr. Jean Luc-Butel President K8 Global.